Pascal and Francis Bibliographic Databases

Help

Search results

Your search

kw.\*:("Cilengitida")

Publication Year[py]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Discipline (document) [di]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Author Country

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Results 1 to 25 of 25

  • Page / 1
Export

Selection :

  • and

Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancerMANEGOLD, Christian; VANSTEENKISTE, Johan; CARDENAL, Felipe et al.Investigational new drugs. 2013, Vol 31, Num 1, pp 175-182, issn 0167-6997, 8 p.Article

αv-Integrin isoform expression in primary human tumors and brain metastasesVOGETSEDER, Alexander; THIES, Svenja; INGOLD, Barbara et al.International journal of cancer (Print). 2013, Vol 133, Num 10, pp 2362-2371, issn 0020-7136, 10 p.Article

Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE-MRI in a longitudinal in vivo studyBAUERLE, Tobias; KOMLJENOVIC, Dorde; MERZ, Maximilian et al.International journal of cancer (Print). 2011, Vol 128, Num 10, pp 2453-2462, issn 0020-7136, 10 p.Article

Integrin control of the transforming growth factor-β pathway in glioblastomaROTH, Patrick; SILGINER, Manuela; WELLER, Michael et al.Brain. 2013, Vol 136, pp 564-576, issn 0006-8950, 13 p., 2Article

Perspectives dans le traitement des Tumeurs CérébralesDHERMAIN, Frédéric; SANSON, Marc.Oncologie (Paris). 2008, Vol 10, issn 1292-3818, 7 p., SUP5Serial Issue

Phase I and correlative biology study of cilengitide in patients with recurrent malignant gliomaBURT NABORS, L; MIKKELSEN, Tom; DIMITRIOS COLEVAS, A et al.Journal of clinical oncology. 2007, Vol 25, Num 13, pp 1651-1657, issn 0732-183X, 7 p.Article

Cilengitide response in ultra-low passage glioblastoma cell lines: relation to molecular markersMULLINS, Christina S; SCHUBERT, Julia; SCHNEIDER, Björn et al.Journal of cancer research and clinical oncology. 2013, Vol 139, Num 8, pp 1425-1431, issn 0171-5216, 7 p.Article

Integrin Inhibitor Cilengitide for the Treatment of Glioblastoma: A Brief Overview of Current Clinical ResultsSCARINGI, Claudia; MINNITI, Giuseppe; CAPORELLO, Paola et al.Anticancer research. 2012, Vol 32, Num 10, pp 4213-4223, issn 0250-7005, 11 p.Article

Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed GlioblastomaSTUPP, Roger; HEGI, Monika E; PIETSCH, Torsten et al.Journal of clinical oncology. 2010, Vol 28, Num 16, pp 2712-2718, issn 0732-183X, 7 p.Article

Assessment of the biological and pharmacological effects of the ανβ3 and ανβ5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumorsHARIHARAN, S; GUSTAFSON, D; BARON, A et al.Annals of oncology. 2007, Vol 18, Num 8, pp 1400-1407, issn 0923-7534, 8 p.Article

Cilengitide affects tumor compartment, vascularization and microenvironment in experimental bone metastases as shown by longitudinal 18F-FDG PET and gene expression analysisBRETSCHI, Maren; CAIXIA CHENG; WITT, Hendrik et al.Journal of cancer research and clinical oncology. 2013, Vol 139, Num 4, pp 573-583, issn 0171-5216, 11 p.Article

Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I partVERMORKEN, J. B; GUIGAY, J; MESIA, R et al.British journal of cancer. 2011, Vol 104, Num 11, pp 1691-1696, issn 0007-0920, 6 p.Article

Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependencyMIKKELSEN, Tom; BRODIE, Chaya; GOODMAN, Simon L et al.International journal of cancer (Print). 2009, Vol 124, Num 11, pp 2719-2727, issn 0020-7136, 9 p.Article

Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma MultiformeREARDON, David A; FINK, Karen L; SCHIFF, David et al.Journal of clinical oncology. 2008, Vol 26, Num 34, pp 5610-5617, issn 0732-183X, 8 p.Article

Cilengitide targeting of αvβ3 integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenograftsBURKE, Patricia A; DENARDO, Sally J; MIERS, Laird A et al.Cancer research (Baltimore). 2002, Vol 62, Num 15, pp 4263-4272, issn 0008-5472Article

Combination therapy of cilengitide with belotecan against experimental glioblastomaKIM, Young-Hoon; JIN KYUNG LEE; KIM, Bokyong et al.International journal of cancer (Print). 2013, Vol 133, Num 3, pp 749-756, issn 0020-7136, 8 p.Article

The Integrin Inhibitor Cilengitide Affects Meningioma Cell Motility and InvasionWILISCH-NEUMANN, Annette; KLIESE, Nadine; KIRCHES, Elmar et al.Clinical cancer research (Print). 2013, Vol 19, Num 19, pp 5402-5412, issn 1078-0432, 11 p.Article

The αVβ3/αVβ5 integrin inhibitor cilengitide augments tumor response to melphalan isolated limb perfusion in a sarcoma modelTEN HAGEN, Timo L. M; SEYNHAEVE, Ann L. B; DE WIEL-AMBAGTSHEER, Gisela Aan et al.International journal of cancer (Print). 2013, Vol 132, Num 11, pp 2694-2704, issn 0020-7136, 11 p.Article

The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanomaTENTORI, Lucio; SUSANNA DORIO, Annalisa; MUZI, Alessia et al.Oncology reports. 2008, Vol 19, Num 4, pp 1039-1043, issn 1021-335X, 5 p.Article

Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumoursESKENS, F. A. L. M; DUMEZ, H; HOEKSTRA, R et al.European journal of cancer (1990). 2003, Vol 39, Num 7, pp 917-926, issn 0959-8049, 10 p.Article

Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase 1/11 ADVANTAGE trial (phase II part)VERMORKEN, J. B; PEYRADE, F; BRÜMMENDORF, T. H et al.Annals of oncology. 2014, Vol 25, Num 3, pp 682-688, issn 0923-7534, 7 p.Article

A Safety Run-In and Randomized Phase 2 Study of Cilengitide Combined With Chemoradiation for Newly Diagnosed Glioblastoma (NABTT 0306)NABORS, L. Burt; MIKKELSEN, Thomas; FISHER, Joy D et al.Cancer. 2012, Vol 118, Num 22, pp 5601-5607, issn 0008-543X, 7 p.Article

Cilengitide inhibits metastatic bone colonization in a nude rat modelBRETSCHI, Maren; MERZ, Maximilian; KOMLJENOVIC, Dorde et al.Oncology reports. 2011, Vol 26, Num 4, pp 843-851, issn 1021-335X, 9 p.Article

Phase I Clinical Trial of Cilengitide in Children With Refractory Brain Tumors : Pediatric Brain Tumor Consortium Study PBTC-012MACDONALD, Tobey J; STEWART, Clinton F; KUN, Larry E et al.Journal of clinical oncology. 2008, Vol 26, Num 6, pp 919-924, issn 0732-183X, 6 p.Article

Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumourRAGUSE, Jan-Dirk; GATH, Hans Joachim; BIER, Jürgen et al.Oral oncology (1997). 2004, Vol 40, Num 2, pp 228-230, issn 1368-8375, 3 p.Article

  • Page / 1